Oppenheimer Reiterates “Outperform” Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “outperform” rating reiterated by equities researchers at Oppenheimer in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $20.00 target price on the stock. Oppenheimer’s price objective would suggest a potential upside of 387.80% from the stock’s current price.

Several other brokerages also recently issued reports on ZNTL. Stifel Nicolaus cut their price target on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, June 18th. Morgan Stanley reissued an “equal weight” rating and issued a $8.00 target price (down from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research report on Monday, August 12th. Jefferies Financial Group restated a “hold” rating and set a $6.00 target price (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Finally, Wells Fargo & Company cut Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $29.00 to $9.00 in a report on Tuesday, June 18th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.78.

Zentalis Pharmaceuticals Trading Up 11.4 %

NASDAQ ZNTL opened at $4.10 on Monday. Zentalis Pharmaceuticals has a 1-year low of $2.83 and a 1-year high of $23.52. The stock’s 50 day moving average is $3.54 and its two-hundred day moving average is $8.62. The company has a market capitalization of $291.21 million, a price-to-earnings ratio of -1.23 and a beta of 1.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the previous year, the company posted ($1.85) earnings per share. On average, analysts predict that Zentalis Pharmaceuticals will post -2.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ZNTL. ProShare Advisors LLC lifted its holdings in Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after buying an additional 1,274 shares during the period. Quest Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth $38,000. Charles Schwab Investment Management Inc. grew its stake in shares of Zentalis Pharmaceuticals by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after purchasing an additional 3,759 shares during the period. Values First Advisors Inc. increased its holdings in Zentalis Pharmaceuticals by 5.4% in the second quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock valued at $306,000 after purchasing an additional 3,859 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Zentalis Pharmaceuticals by 66.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 13,634 shares of the company’s stock valued at $215,000 after buying an additional 5,446 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.